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Antidepressants Misrepresented 
Steve Rockoff 
In the first week of 2010, a study performed by researchers at the University of Pennsyl-
vania made waves as it circulated through every major national news outlet.  The study, a meta-
analysis of six independent studies conducted at various points in the past 20 years, was con-
ducted in order to determine the relative benefit of antidepressant medications over a placebo, 
for depressed patients with a varied range of baseline symptom severities.1  The results of the 
study led to the publication of articles in various medias with titles such as U.S. News & World 
Report’s “Do You Really Need That Antidepressant?” and USA Today’s “Study: Antidepres-
sant lift may be all in your head.”2, 3  Indeed, the conclusion that the researchers came to was 
that in cases of mild or moderate depression, some of those common antidepressants were no 
more useful than a mere sugar pill. 
I was fairly troubled when I perused through the various articles and stories that covered 
this study, seeing that in many cases, the media was up to its usual old tricks of sensationalizing 
and misrepresenting the most recent “hot medical study” of the week.  Sending a message to the 
American people that trivializes the effects or usefulness of antidepressants is a very precarious 
game, and as I shall imminently elaborate, even more unfortunate when that message is based 
on a study with several inherent flaws. 
The class of drugs known as ‘antidepressant 
medications’ (ADMs) encompasses a multitude 
of compounds whose members are often pre-
scribed for a wide variety of psychiatric disor-
ders.  One of these is major depressive disorder, a 
multi-factorial mood disorder that most likely 
arises due to a complex interaction of biological, 
psychological, and social factors including drug 
and substance abuse.  Depression is a disorder 
that can range from having mildly intrusive to 
severely debilitating effects on a patient’s 
life.  The most characteristic psychological 
symptoms of depression are low mood, low self-esteem, loss of interest & pleasure, excessive 
rumination, and feelings of worthlessness.  These are more often than not accompanied by the 
physical symptoms of insomnia, drastically decreased appetite, weight loss, headaches, and fa-
tigue.4 
The identification and treatment of depression is of great interest to the American peo-
ple.  While the lifetime prevalence of depression in most countries falls between 8-12%, the 
United States has roughly 17% of its population afflicted.5  Antidepressants are the third-most 
widely prescribed class of drug in the US, with an estimated 10% of women and 4% of men 
taking them.2  Unfortunately, it is widely agreed in the medical community that not only is de-
pression under-diagnosed, but that diagnosed patients are often under-treated!  The investiga-
tors actually had a praiseworthy motive for the study at hand; their literature search revealed a 
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marked paucity of pharmacological studies in which participants had baseline scores below 23 
on the Hamilton Depression Rating Scale (HDRS), the minimum score for “very severe depres-
sion”.  Bearing in mind that the majority of ADM patients may be considerably below a score 
of 23  (it was shown that 71% of participants in a recent survey had HDRS scores less than 22), 
the investigators’ task at hand of examining those who were “less” depressed would seem very 
worthwhile.6 
It is important to bear in mind that in the world of depression treatment, antidepressants 
share the throne with psychotherapy.  Or at least, ideally they do.  In the modern world’s quick-
fix, medicated society, too often psychotherapy is overlooked or unwanted.  Indeed, from 1996 
to 2005, the use of ADM in the U.S. doubled, while the use of psychotherapy declined.7  When 
in reality, the various forms of psychotherapy (which include cognitive behavioral therapy, 
group therapy, and psychoanalysis) may have just as much, if not more, to offer than ADMs in 
terms of treatment. 
This past summer, I worked in the Behavioral Health Center (BHC) of Westchester Medical 
Center under the supervision of B-2 inpatient unit physician Dr. Jay Draoua.  I spent the bulk of 
my days observing or participating in the evaluations and treatments of the admitted patients, 
many of which had depression.  As a rule, my current personal standpoint as an idealistic bur-
geoning medical student is still one that prefers to avoid pharmacological treatment as much as 
possible, especially when other forms of treatment are available.  This means that for psychiat-
ric disorders such as depression, in addition to the helpful standbys of exercising, eating 
healthy, and pushing one’s self into socialization, I highly advocate psychotherapy as a thera-
peutic tool.  With the patients I have observed in the BHC, antidepressants have been highly 
useful in the stabilization of recently admitted patients; however, antidepressants are not sup-
posed to be advertised as a long-term solution to for depression.  As I have witnessed, to truly 
treat depression, one must examine the core of the patient, explore the roots of the underlying 
issues or events that triggered their pain, and have them come to an understanding with their 
illness.  The patient has to approach an appreciation and respect for themselves.  Only then can 
you put depression beyond the reaches of remission, something that antidepressants are not able 
to do. 
However, as I mentioned, antidepressants do have substantial merits of their own.  The idea 
is to normalize certain neurotransmitters in the brain that are involved in regulating mood, thus 
potentially alleviating the altered levels which are sometimes associated with depression.  This 
can provide immeasurable benefits for the patient on their road to recovery.  Often, patients 
must be brought to a higher level of functioning before any meaningful psychotherapy can even 
begin.  In other cases, they can stabilize a mildly – or moderately -– affected patient from re-
lapsing into a severe episode.  Perhaps most often, they can provide a subtle boost in function-
ing for men and women going about their daily lives and work, without which they would be 
increasingly burdened by whichever depressive affliction haunts them. 
For these reasons, I feel somewhat offended by the way in which this study’s results are pre-
sented by the authors and the media.  As I perused the content of this meta-analysis, I built a list 
of several troubling concerns I had regarding the methods involved, and how the results were 
portrayed. 
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To begin with, the literature search which was conducted by the investigators to find studies 
for their meta-analysis reached all the way back to 1980.  Out of the over 2000 studies they 
searched, their exclusion criteria (for studies without placebo controls, or ones examining spe-
cial subpopulations, etc.) narrowed the number of studies they included in their final meta-
analysis down to just six.  Of these six, three of them compared the ADM imipramine to pla-
cebo, and three compared the ADM paroxetine to placebo.  Imipramine belongs to an older 
class of drugs developed in the 1950’s, the tricyclics (TCAs), a highly effective group of antide-
pressants which are still used for treatment-resistance depression when other drugs fail, though 
they can sometimes cause mania or hypomania on a maintained dosage.8, 9  Today, the TCAs 
are less popular due to the advent of antidepres-
sant drug classes with less severe side effects, 
such as the selective serotonin reuptake inhibi-
tors (SSRIs).  A 2007 ranking of the most com-
monly prescribed ADMs in the U.S. put 
imipramine at thirteenth with 1.524 million, 
which is less than one-third of the twelfth-
ranked nortriptyline and a mere fraction of the 
top four ranked ADMs (which all top 20 mil-
lion on their own).10  Using such a rarely-
prescribed and antiquated drug to represent the 
whole range of ADMs and their supposed inef-
fectiveness on mild depression is just poor 
practice, in my opinion.  The investigators 
make note of several of their study’s limitations, but this is not one of them.  It is quite a shame 
that they have allowed ADMs to be presented to the public this way, with half of their data 
coming from this particular drug. 
Paroxetine, a SSRI and the fifth-most prescribed ADM in the U.S. in 2007, was the other 
drug used in the studies.  However, compared to the three SSRIs that were more popular 
(sertraline, escitalopram, and fluoxetine), paroxetine is associated with several concerning side 
effects such as weight gain, increased risk of suicidality, and high risk of withdrawal syn-
drome.11, 12, 13  Again, not a drug most representative of the antidepressants Americans would be 
likely to use.  Neither one of the two ADMs used on patients in the meta-analsyis are popularly 
used as first-line agents for depression.  Even if they were used as the first treatment, as they 
were in these studies, it is well known (and even taught to us in first year Behavioral Sciences 
in medical school) that very often the first-line of treatment is not effective, and that two or 
three classes of ADMs may be tried before finding one that the patient responds to. 
Another area of concern to me was that the investigators set a minimum criterion of a 6-
week treatment duration period for symptom scores when selecting studies to include.  In fact, 
the average treatment duration for the six studies was only a little over eight weeks, which 
seems to be an alarmingly short time to stop the recording data for a depression study.  ADMs 
are renowned for their need to take several weeks in order to begin to take effect.  Two to three 
weeks is usually the minimum standard, and for an ADM’s effect to take even longer than that 
is by no means rare.  In particular, the rate of symptom improvement can greatly vary by drug 
and by person.  Imipramine in particular has been shown to have a slower rate of symptom im-
provement than other drugs in the treatment of depression, and even though it can lag behind its 
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peers after six weeks of treatment, its effect is by no means over – a continued improvement in 
symptom score is still observed beyond that six week mark.14   The investigators’ findings seem 
to, unfortunately, only apply to acute treatment, not the continuous or maintenance ADM treat-
ment that millions of Americans find themselves on. 
Further flaws in this recent study can be found in the types of patients who were chosen to 
be excluded from this meta-analysis.  Almost 600 studies were stricken from inclusion because 
the depression patients were dysthymic or were from a special sub-population (i.e. a certain eth-
nicity).  Dysthymia is a mood disorder which is best described as chronic depression, but at a 
lesser intensity… the patient must have the symptoms of a depressed mood for at least two 
years, but without the presence of a major depressive episode.  The very definition of dysthy-
mia, which is to have a “less severe” depression, seems to suggest that its patients would suit 
perfectly for the present meta-analysis, which has a great interest in patients who score lower on 
a depressive symptom scale.  If the proposed trend of less-severely depressed patients showed 
an equal response to placebo was also discovered in dysthymic patients, which would contrib-
ute greatly to the investigator’s current conclusions.  However, it has been well shown over the 
years that the three main classes of ADMs (SSRI, TCA, and monoamine oxidase inhibitors) 
have a noted pharmacological effect over placebo in the treatment of dysthymia patients, espe-
cially in the short term.15  It should also be noted that the results of this meta-analysis do not 
apply to inpatient populations or children, two sizable groups which were also excluded from 
the study. 
My last criticism of the meta-analysis at hand is the use of the depression symptom scoring 
criteria.  All six studies involved used the Hamilton Depression Rating Scale (HDRS), in which 
patients scoring 8-13 have “mild” depression, 14-18 are “moderate”, 19-22 are “severe”, and 
greater than 23 are “very severe”.  The results of the current analysis demonstrated that there 
was a small effective difference between ADM and placebo when the patients had a baseline 
below a score of 23.  In addition, the National Institute for Clinical Excellence’s standard for 
significant difference between ADM and placebo (meaning the HDRS difference is 3 or 
greater) was not met until patients had a baseline of 25 or greater.  
Most media articles reporting this study emulate the claim that ADMs only work if one is 
“severely depressed,” i.e. has a HDRS score of 23 or greater.  However, taking the ratings on 
the HDRS scale literally is very misleading.  Resistance to the use of HRDS labels by mental 
health practitioners is nothing new.  “The Hamilton concept of ‘severe’, I think many psychia-
trists would think of as ‘moderate’,” said Dr. Mark Olfson, a professor of clinical psychiatry at 
Columbia University.16  The Hamilton scale, developed in the 1960’s, is widely used because of 
tradition in the field, but in reality it suffers from a sort of “grade inflation” that can classify pa-
tients in very misleading, and especially more severe, ways. 
The authors of this meta-analysis recognized some of the limitations of their study, particu-
larly the caveat about the psychometric measuring properties of the HDRS.  However, many of 
the items I noted above were not spoken for.  I would agree with the author’s call for more stud-
ies examining patients with a wide range of baseline depression severities, as their claim that 
there is relatively little data on lesser depressed patient’s responses to antidepressants appears to 
be valid.  I would hope, though, that with future studies to be done, they could rectify some of 
my current critiques regarding the methods of analysis, and accurately present their conclusions 
to the public and media. 
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